NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Kazia Therapeutics Limited (KZIA) Stock Analysis

Kazia Therapeutics Limited (KZIA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KZIA

$12.31

+$0.15 (+1.23%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KZIA with… →

KZIA Key Statistics

As of Sep 4, 2026
Trading
Open
$12.00
Previous Close
$12.16
Day's Range
11.77–12.62
52-Week Range
4.86–17.40
Volume
414.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.15
Valuation
Market Cap
$140.67M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.01
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
74.09
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.70
Financials (FY)
Revenue (FY)
$42.00K−98.18%
Net Income (FY)
−$20.70M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
11.43M
1-Year Return
+52.16%
Dividend and dates
Avg Volume
223.45K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KZIA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+78.66%
2025−22.15%
2024−59.77%
2023−27.87%
2022−92.76%
2021−2.55%
2020+99.08%
2019+78.60%
2018−23.58%
2017−45.92%
2016 (partial year)−20.54%

As of September 4, 2026.

KZIA Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$42.00K−$20.70M−49290.5%
2024$2.31M−$26.78M−1160.2%
2023$0.00−$20.47M—
2022$0.00−$25.01M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$42.00K—−$14.22M−$20.70M−49290.5%
2024$2.31M—−$28.46M−$26.78M−1160.2%
2023$0.00—−$24.15M−$20.47M—
2022$0.00—−$25.40M−$25.01M—

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

KZIA Valuation vs Biotechnology Median

Median of 656 stocks
MetricKZIABiotechnology medianvs median
P/S ratio74.0915.264.9x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kazia Therapeutics Limited (KZIA) carries a market capitalisation of $140.67M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 6 employees.

The 52-week range on file runs from $4.86 to $17.40. KZIA last closed at $12.31 on September 4, 2026. That is +$0.15 (+1.23%) against the previous close. The latest close sits 153.29% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $42.00K. That is −98.18% against the prior fiscal year, when revenue was $2.31M. The same year closed with a net loss of $20.70M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −7.7.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $42.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.01. Measured against sales, the shares trade at 74.09 times revenue. On price-to-sales that is 4.9 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +52.16%. Measured over 10 years, that is −29.33% a year compounded. Beta against the wider market is reported at 2.15. Annualized volatility over the trailing 10 years is 137.36%.

Growth & Income

The record shows no dividend for KZIA.

Across the complete calendar years on file, 2020 returned +99.08% and 2022 returned −92.76%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is +78.66%.

Peer Comparison

Kazia Therapeutics Limited (KZIA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kazia Therapeutics Limited KZIA $140.67M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Kazia Therapeutics Limited has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Kazia Therapeutics Limited

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Visit website →